2008 has been a important year for Pritor
®/Kinzal
® and cardio & vascular protection in general starting from the first
presentation of the results of the landmark
ONTARGET® trial in March at the American College of Cardiology Congress, following this the release of
PRoFESS™ and the most recent TRANSCEND
® results announced at the European Society of Cardiology Congress. In consideration of these major publications, the symposium presented an ideal forum for the data to be collated, reviewed and discussed by leading experts from around the globe.
The symposium welcomed discussions and lectures from these experts, who form part of the ICMA faculty, focusing on the trial’s outcomes and other essential clinical issues surrounding morbi-mortality trials, new evidence and guidelines in clinical practice. Presentations included those of Prof. Henry Elliott and Dr. Alejandro de la Sierra who spoke on the
TRANSCEND® and
PRoFESS™ results respectively. In addition, Prof. Athanase Benetos presented on the State of the art of RAAS blockers in high-risk patients before 2008. Dr. Roland Asmar raised the question whether evidence only originates from morbi-mortality Trials. Following these interesting presentations, interactive country workshops were held allowing review of the topics discussed in the morning sessions, resulting in exciting debate on current and future therapies due to the new results of the
ONTARGET® Trial Program.
